{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=53", "query": { "intervention": "A PROTEIN level", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1386, "total_pages": 139, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:11:18.304Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00325416", "title": "Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "melphalan", "type": "DRUG" }, { "name": "topotecan (TPT)", "type": "DRUG" }, { "name": "Autologous Stem Cell Rescue", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2001-11-19", "completion_date": "2018-01-30", "has_results": true, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325416" }, { "nct_id": "NCT01912963", "title": "Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "eribulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-09", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01912963" }, { "nct_id": "NCT02225132", "title": "Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "15 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2014-08-23", "completion_date": "2018-05-24", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02225132" }, { "nct_id": "NCT03064867", "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell-lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-06-26", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 3, "location_summary": "St Louis, Missouri • Cleveland, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064867" }, { "nct_id": "NCT03079245", "title": "Improving Antimicrobial Prescribing Practices in the Neonatal ICU", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infants in Neonatal Intensive Care Units" ], "interventions": [ { "name": "Education Plus (E+)", "type": "OTHER" }, { "name": "Clinical Decision Support", "type": "OTHER" }, { "name": "Prescriber Audit and Feedback", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6184, "start_date": "2009-05-01", "completion_date": "2012-04-30", "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 4, "location_summary": "Wilmington, Delaware • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03079245" }, { "nct_id": "NCT02213029", "title": "A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Embryo Transfer" ], "interventions": [ { "name": "Epelsiban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oxytocin", "type": "DRUG" }, { "name": "Ortho-Cylcen (21)® tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 33, "start_date": "2014-08-28", "completion_date": "2016-02-07", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213029" }, { "nct_id": "NCT02703272", "title": "A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 72, "start_date": "2016-07-01", "completion_date": "2021-06-11", "has_results": true, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02703272" }, { "nct_id": "NCT00450801", "title": "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2004-04", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2015-11-10", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450801" }, { "nct_id": "NCT07877194", "title": "A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma, Clear Cell" ], "interventions": [ { "name": "Ivonescimab (dose level 1) combined with Cadonilimab", "type": "DRUG" }, { "name": "Ivonescimab (dose level 2) combined with Cadonilimab", "type": "DRUG" }, { "name": "Ivonescimab combined with Ipilimumab", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Nivolumab combined with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-10-19", "completion_date": "2029-12-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07877194" }, { "nct_id": "NCT00841100", "title": "Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Phenylketonuria" ], "interventions": [ { "name": "Kuvan", "type": "DRUG" }, { "name": "Diet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 21, "start_date": "2008-12", "completion_date": "2011-07-19", "has_results": true, "last_update_posted_date": "2019-12-03", "last_synced_at": "2026-10-22T08:11:18.304Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00841100" } ] }